Red cell-derived microparticles (RMP) as haemostatic agent

Wenche Jy; Max E. Johansen; Carlos Bidot; Lawrence L. Horstman; Yeon S. Ahn

doi:10.1160/TH12-12-0941

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2013; 110(04): 751-760
DOI: 10.1160/TH12-12-0941

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

Red cell-derived microparticles (RMP) as haemostatic agent

Authors

Wenche Jy

¹The Wallace H Coulter Platelet Laboratory, Division of Hematology/Oncology, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA
Max E. Johansen

¹The Wallace H Coulter Platelet Laboratory, Division of Hematology/Oncology, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA
Carlos Bidot

¹The Wallace H Coulter Platelet Laboratory, Division of Hematology/Oncology, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA
Lawrence L. Horstman

¹The Wallace H Coulter Platelet Laboratory, Division of Hematology/Oncology, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA
Yeon S. Ahn

¹The Wallace H Coulter Platelet Laboratory, Division of Hematology/Oncology, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA

Abstract

Summary

Among circulating cell-derived microparticles, those derived from red cells (RMP) have been least well investigated. To exploit potential haemostatic benefit of RMP, we developed a method of producing them in quantity, and here report on their haemostatic properties. High-pressure extrusion of washed RBC was employed to generate RMP. RMP were identified and enumerated by flow cytometry. Their size distribution was assessed by Doppler electrophoretic light scattering analysis (DELSA). Interaction with platelets was studied by platelet aggregometry, and shear-dependent adhesion by Diamed IMPACT-R. Thrombin generation and tissue factor (TF) expression was also measured. The effect of RMP on blood samples of patients with bleeding disorders was investigated ex vivo by thromboelastography (TEG). Haemostatic efficacy in vivo was assessed by measuring reduction of blood loss and bleeding time in rats and rabbits. RMP have mean diameter of 0.45 μm and 50% of them exhibit annexin V binding, a proxy for procoagulant phospholipids (PL). No TF could be detected by flow cytometry. At saturating concentrations of MPs, RMP generated thrombin robustly but after longer delay compared to PMP and EMP. RMP enhanced platelet adhesion and aggregation induced by low-dose ADP or AA. In TEG study, RMP corrected or improved haemostatic defects in blood of patients with platelet and coagulation disorders. RMP reduced bleeding time and blood loss in thrombocytopenic rabbits (busulfan-treated) and in Plavix-treated rats. In conclusion, RMP has broad haemostatic activity, enhancing both primary (platelet) and secondary (coagulation) haemostasis, suggesting potential use as haemostatic agent for treatment of bleeding.

Keywords

Animal bleeding models - haemostatic agent - RMP–platelet interaction - red cell microparticles (RMP) - thromboelastography

Volltext

Referenzen

References
1 Burnier L, Fontana P, Kwak BR. et al. Cell-derived microparticles in haemostasis and vascular medicine.. Thromb Haemost 2009; 101: 439-451.
2 Chang CP, Zhao J, Wiedmer T. et al. Contribution of platelet microparticle formation and granule secretion to the transmembrane migration of phosphatidylserine.. J Biol Chem 1993; 268: 7171-7178.
3 Ahn YS. Cell-derived microparticles: ‘Miniature envoys with many faces.’. J Thromb Haemost 2005; 3: 884-887.
4 Tesse A, Martinez MC, Meziani F. et al. Origin and biological significance of shed-membrane microparticles.. Endocr Metab Immune Disord Drug Targets 2006; 6: 287-294.
5 Morel O, Jesel L, Freyssinet JM. et al. Cellular mechanisms underlying the formation of circulating microparticles.. Arterioscler Thromb Vasc Biol 2011; 31: 15-26.
6 Andrews D, Low P. Role of red blood cells in thrombosis.. Curr Opin Hematol 1999; 6: 76-82.
7 Mannucci PM. Red cells playing as activated platelets in thalassemia intermedia.. J Thromb Haemost 2010; 8: 2149-2151.
8 Borenstain-Ben Yashar V, Barenholz Y, Hy-Am E. et al. Phosphatidylserine in the outer leaflet of red blood cells from -thalassemia patients may explain the chronic hypercoagulable state and thrombotic episodes.. Am J Hematol 1993; 44: 63-65.
9 Chao FC, Kim BK, Houranieh AM. et al. Infusible platelet membrane microvesicles: A potential transfusion substitute for platelets.. Transfusion 1996; 36: 536-542.
10 Graham SS, Gonchoroff NJ, Miller JL. Infusible platelet membranes retain partial functionality of the platelet GP Ib/IX/V receptor complex.. Am J Clin Path 2001; 115: 144-147.
11 Galan AM, Bozzo J, Herndandez MR. et al. Infusible platelet membranes improve haemostasis in thrombocytopenic blood: experimental studies under flow conditions.. Transfusion 2000; 40: 1074-1080.
12 Jy W, Johansen ME, Bidot Jr C. et al. Interaction of red cell microparticles (RMP) with platelets: Potential role of RMP in haemostasis and thrombosis.. 53rd meeting of ASH, San Diego, CA, Dec. 4-7. Blood. 2011 Suppl: Abstract 43127.
13 Ahn YS, Jy W, Johansen ME. et al. Red cell derived microparticles (RMP) as haemostatic agent to treat bleeding disorders: the mode of action of RMP.. Oral presentation at XXIII ISTH Congress, July 26, 2011, Kyoto, Japan. J Thromb Haemost 2011; (Suppl. 09) 269 Abstract O-TU-030.
14 Jy W, Johansen ME, Horstman LL. et al. Haemostatic properties of red cell derived microparticles (RMP): Promise of universal haemostatic agent.. Presented at ISTH SSC meeting in June 29, 2012, Liverpool, England. Available at: http://www.multiwebcast.com/isth/2012/ssc/20988.
15 Jy W, Bidot Jr C, Nunez S. et al. Red Cell-Derived Microparticles (RMP) As Haemostatic Agent: Evaluation in a Rabbit Ear Bleeding Model. ASH Annual Meeting Abstracts.. Blood 2012; 120: 2238.
16 Jy W, Bidot L, Jimenez JJ. et al. Thrombin generation profiles are qualitatively and quantitatively distinct in microparticles derived from red cells (RMP), platelets (PMP), and endothelia (EMP).. Presented at 48th annual mtng, Amer. Soc. Hematol., Orlando, FL, Dec. 9-12. Blood 2006; 108: 499a Abstract 1759.
17 Hemker HC. Calibrated automated thrombin generation measurement in clotting plasma.. Pathophysiol Haemost Thromb 2003; 33: 4-15.
18 Bidot L, Jy W, Bidot Jr C. et al. Microparticle-mediated thrombin generation assay: increased activity in patients with recurrent thrombosis.. J Thromb Haemost 2007; 6: 913-919.
19 Blajchman MA, Lee DH. The thrombocytopenic rabbit bleeding time model to evaluate the in vivo haemostatic efficacy of platelets and platelet substitutes.. Trans Med Rev 1997; 11: 95-105.
20 Panes O, Matus V, Saenz CG. et al. Platelets synthesize and express functional tissue factor.. Blood 2007; 109: 5242-5250.
21 Skeppholm M, Mobarrez F, Malmqvist K. et al. Platelet-derived microparticles during and after acute coronary syndrome.. Thromb Haemost 2012; 107: 1122-1129.
22 Bouchard BA, Mann KG, Butenas S. No evidence for tissue factor on platelets.. Blood 2010; 116: 854-855.
23 Van der Meijden PE, Van Schilfgaard M, Van Oerle R. et al. Platelet- and erythrocyte-derived microparticles trigger thrombin generation via FXIIa.. J Thromb Haemost 2012; 10: 1355-1362.
24 Rubin O, Delobel J, Prudent M. et al. Red blood cell-derived microparticles isolated from blood units initiate and propagate thrombin generation.. Transfusion. 2012 Epub ahead of print.
25 Jy W, Ahn YS, Horstman LL. et al. Microparticles from RBC (RMP) exhibit haemostatic activities in vitro and in vivo, and appear to protect ITP patients from thrombocytopenic bleeding.. Presented at: XIV International Symposium on Atherosclerosis, Rome, Italy, June 18-22. Atherosclerosis 2006; (Suppl. 07) 291 Abstract Tu-P10:485.
26 Lominadze D, Dean WL. Involvement of fibrinogen specific binding in erythrocyte aggregation.. FEBS Lett 2002; 517: 41-44.
27 Carvalho FA, Connell S, Miltenberger-Miltenyi G. et al. Atomic force microscopy-based molecular recognition of a fibrinogen receptor on human erythrocytes.. ACS Nano 2010; 4: 4609-4620.
28 Jy W, Ricci M, Shariatmadar S. et al. Microparticles in stored red blood cells as potential mediators of transfusion complications.. Transfusion 2011; 51: 886-893.
29 Salzer U, Hinterdorfer P, Hunger U. et al. Ca2+ dependent vesicle release from erythrocytes involves stomatin-specific lipid rafts, synexin (annexin VIII), and sorcin.. Blood 2002; 99: 2569-2577.
30 Lopez JA, Del Conde I, Shrimpton CN. Receptors, rafts, and microvesicles in thrombosis and inflammation.. J Thromb and Haemost 2005; 3: 1737-1741.
31 Del Conde I, Shrimpton CN, Thiagarajan P. et al. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation.. Blood 2005; 106: 1604-1611.